BioCryst's Orladeyo Application Under Review In Israel For Hereditary Angioedema

by Vandana Singh, Benzinga Editor

June 16, 2021 7:50 AM | 27 seconds read | Make a Comment

The Israeli Ministry of Health has accepted for review BioCryst Pharmaceuticals Inc's BCRX application for Orladeyo to prevent recurrent attacks in patients with hereditary angioedema (HAE) 12 years and older.
The Israeli Ministry of Health also has granted an accelerated review.
In addition, BioCryst has entered into a distribution and supply agreement granting Neopharm Ltd to commercialize Orladeyo in Israel.
Price Action: BCRX shares are up 1.6% at $15.86 during the premarket session on the last check Wednesday.

Posted In: Biotech News Health Care FDA General Briefs hereditary angioedema

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.